These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 34978748)

  • 1. Person-centred care and short oral treatment for rifampicin-resistant tuberculosis improve retention in care in Kandahar, Afghanistan.
    Mesic A; Ishaq S; Khan WH; Mureed A; Mar HT; Khaing EE; Bermudez-Aza E; Rose L; Lynen L; Seddiq MK; Amirzada HK; Keus K; Decroo T
    Trop Med Int Health; 2022 Feb; 27(2):207-215. PubMed ID: 34978748
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Translating drug resistant tuberculosis treatment guidelines to reality in war-torn Kandahar, Afghanistan: A retrospective cohort study.
    Mesic A; Khan WH; Lenglet A; Lynen L; Ishaq S; Phyu EHH; Mar HT; Oraegbu A; Seddiq MK; Amirzada HK; Fernhout J; Kamau C; Ariti C; Gomez D; Decroo T
    PLoS One; 2020; 15(8):e0237787. PubMed ID: 32822375
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment outcome of tuberculosis treatment regimens in Kandahar, Afghanistan.
    Rahimi BA; Rahimy N; Ahmadi Q; Hayat MS; Wasiq AW
    Indian J Tuberc; 2020 Jan; 67(1):87-93. PubMed ID: 32192624
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Short oral treatment regimens for rifampicin-resistant tuberculosis are safe and effective for young children: results from a field-based, non-randomised clinical trial from Kandahar, Afghanistan.
    Mesic A; Decuyper I; Ishaq S; Azizi T; Ziamal FH; Amiri S; Keus K; Thandar Pyae M; Mangal KM; Amirzada HK; Rasooli A; Aloudal MR; Daldar MZ; Decroo T
    Eur Respir J; 2024 May; 63(5):. PubMed ID: 38782466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient and health-care provider experience of a person-centred, multidisciplinary, psychosocial support and harm reduction programme for patients with harmful use of alcohol and drug-resistant tuberculosis in Minsk, Belarus.
    Harrison RE; Shyleika V; Falkenstein C; Garsevanidze E; Vishnevskaya O; Lonnroth K; Sayakci Ö; Sinha A; Sitali N; Skrahina A; Stringer B; Tan C; Mar HT; Venis S; Vetushko D; Viney K; Vishneuski R; Carrion Martin AI
    BMC Health Serv Res; 2022 Sep; 22(1):1217. PubMed ID: 36180873
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Person-centred care in practice: perspectives from a short course regimen for multi-drug resistant tuberculosis in Karakalpakstan, Uzbekistan.
    Horter S; Stringer B; Gray N; Parpieva N; Safaev K; Tigay Z; Singh J; Achar J
    BMC Infect Dis; 2020 Sep; 20(1):675. PubMed ID: 32938422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incremental Cost Effectiveness of Bedaquiline for the Treatment of Rifampicin-Resistant Tuberculosis in South Africa: Model-Based Analysis.
    Schnippel K; Firnhaber C; Conradie F; Ndjeka N; Sinanovic E
    Appl Health Econ Health Policy; 2018 Feb; 16(1):43-54. PubMed ID: 28980217
    [TBL] [Abstract][Full Text] [Related]  

  • 8. "This is not my body": Therapeutic experiences and post-treatment health of people with rifampicin-resistant tuberculosis.
    Loveday M; Hlangu S; Larkan LM; Cox H; Daniels J; Mohr-Holland E; Furin J
    PLoS One; 2021; 16(10):e0251482. PubMed ID: 34662887
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety, effectiveness, and adherence of a short and all-oral treatment regimen for the treatment of rifampicin-resistant tuberculosis in Niger: a study protocol of a pragmatic randomised clinical trial with stratified block randomisation.
    Souleymane MB; Decroo T; Soumana A; Maman Lawan I; Gagara-Issoufou A; Halidou-Moussa S; Ortuño-Gutiérrez N; Adehossi E; Mamadou S; Van Deun A; Piubello A
    Trials; 2022 Dec; 23(1):1011. PubMed ID: 36514153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries.
    Espinal MA; Kim SJ; Suarez PG; Kam KM; Khomenko AG; Migliori GB; Baéz J; Kochi A; Dye C; Raviglione MC
    JAMA; 2000 May; 283(19):2537-45. PubMed ID: 10815117
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence and factors associated with multidrug/rifampicin resistant tuberculosis among suspected drug resistant tuberculosis patients in Botswana.
    Tembo BP; Malangu NG
    BMC Infect Dis; 2019 Sep; 19(1):779. PubMed ID: 31492099
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost comparison of nine-month treatment regimens with 20-month standardized care for the treatment of rifampicin-resistant/multi-drug resistant tuberculosis in Nigeria.
    Bada FO; Blok N; Okpokoro E; Dutt S; Akolo C; Dakum P; Abimiku A
    PLoS One; 2020; 15(12):e0241065. PubMed ID: 33259492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High rates of death and loss to follow-up by 12 months of rifampicin resistant TB treatment in South Africa.
    Hirasen K; Berhanu R; Evans D; Rosen S; Sanne I; Long L
    PLoS One; 2018; 13(10):e0205463. PubMed ID: 30300403
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment outcomes 24 months after initiating short, all-oral bedaquiline-containing or injectable-containing rifampicin-resistant tuberculosis treatment regimens in South Africa: a retrospective cohort study.
    Ndjeka N; Campbell JR; Meintjes G; Maartens G; Schaaf HS; Hughes J; Padanilam X; Reuter A; Romero R; Ismail F; Enwerem M; Ferreira H; Conradie F; Naidoo K; Menzies D
    Lancet Infect Dis; 2022 Jul; 22(7):1042-1051. PubMed ID: 35512718
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Organisation of care for people receiving drug-resistant tuberculosis treatment in South Africa: a mixed methods study.
    Dickson L; Le Roux SR; Mitrani L; Hill J; Jassat W; Cox H; Mlisana K; Black J; Loveday M; Grant A; Kielmann K; Ndjeka N; Moshabela M; Nicol M
    BMJ Open; 2023 Nov; 13(11):e067121. PubMed ID: 37977868
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Travel distance to rifampicin-resistant tuberculosis treatment and its impact on loss to follow-up: the importance of continued RR-TB treatment decentralization in South Africa.
    McNabb KC; Bergman AJ; Patil A; Lowensen K; Mthimkhulu N; Budhathoki C; Perrin N; Farley JE
    BMC Public Health; 2024 Feb; 24(1):578. PubMed ID: 38389038
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of mortality and treatment success during treatment for rifampicin-resistant tuberculosis within the South African National TB Programme, 2009 to 2011: a cohort analysis of the national case register.
    Schnippel K; Shearer K; Evans D; Berhanu R; Dlamini S; Ndjeka N
    Int J Infect Dis; 2015 Oct; 39():89-94. PubMed ID: 26358856
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical perspectives on treatment of rifampicin-resistant/multidrug-resistant TB.
    Cox V; McKenna L; Acquah R; Reuter A; Wasserman S; Vambe D; Ustero P; Udwadia Z; Triviño-Duran L; Tommasi M; Skrahina A; Seddon JA; Rodolfo R; Rich M; Padanilam X; Oyewusi L; Ohler L; Lungu P; Loveday M; Khan U; Khan P; Hughes J; Hewison C; Guglielmetti L; Furin J
    Int J Tuberc Lung Dis; 2020 Nov; 24(11):1134-1144. PubMed ID: 33172520
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High rates of multidrug-resistant and rifampicin-resistant tuberculosis among re-treatment cases: where do they come from?
    Ragonnet R; Trauer JM; Denholm JT; Marais BJ; McBryde ES
    BMC Infect Dis; 2017 Jan; 17(1):36. PubMed ID: 28061832
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors associated with unfavorable treatment outcomes in patients with rifampicin-resistant tuberculosis in Colombia 2013-2015: A retrospective cohort study.
    Chaves-Torres NM; Fadul S; Patiño J; Netto E
    PLoS One; 2021; 16(4):e0249565. PubMed ID: 33852619
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.